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MouseSevere acute respiratory syndrome (SARS) is a highly lethal emerging disease caused by coronavirus SARS-
CoV. New lethal animal models for SARS were needed to facilitate antiviral research. We adapted and
characterized a new strain of SARS-CoV (strain v2163) that was highly lethal in 5- to 6-week-old BALB/c
mice. It had nine mutations affecting 10 amino acid residues. Strain v2163 increased IL-1α, IL-6, MIP-1α,
MCP-1, and RANTES in mice, and high IL-6 expression correlated with mortality. The infection largely
mimicked human disease, but lung pathology lacked hyaline membrane formation. In vitro efficacy against
v2163 was shown with known inhibitors of SARS-CoV replication. In v2163-infected mice, Ampligen™ was
fully protective, stinging nettle lectin (UDA) was partially protective, ribavirin was disputable and possibly
exacerbated disease, and EP128533 was inactive. Ribavirin, UDA, and Ampligen™ decreased IL-6 expression.
Strain v2163 provided a valuable model for anti-SARS research.Introduction
Severe acute respiratory syndrome (SARS) emerged in 2002 in the
Guandong province of southern China as a new infectious respiratory
disease characterized by influenza-like symptoms and signs, but with
a very high mortality rate (Ksiazek et al., 2003; Peiris et al., 2003b).
A novel coronavirus termed SARS-CoVwas identified as the etiological
agent (Drosten et al., 2003a; Drosten et al., 2003b). The World Health
Organization (WHO) reported 8098 SARS cases from November 2002
to July 2003, and approximately 10% of the patients died (http://who.
int/csr/sars/country/table2003_09_23/en/). Subsequent outbreaks
including two laboratory events occurred, but they were rapidly
contained. These outbreaks demonstrated the need for strategies to
treat sporadic cases of SARS disease, including economical lethal
rodent models that would simulate human SARS disease.
Studies on themolecular evolution of SARS-CoV suggested that the
virus emerged from non-human sources (Guan et al., 2003), although
the natural reservoir of the virus has not been positively identified. A
current hypothesis is that the horseshoe bat is the main natural).reservoir of SARS-CoV-like viruses (Hon et al., 2008; Li et al., 2005b). A
number of SARS-CoV-like viruses have been isolated from bats,
although the full lineage for the ancestors of SARS-CoV remains
uncharacterized (Hon et al., 2008). Virus transmission to humansmay
have occurred when civet cats, infected by bats, were traded on
Chinese wet markets (Guan et al., 2003).
Severe SARS-CoV infections in humans are characterized by diffuse
alveolar damage and sparse inflammatory infiltrates (Chen and
Subbarao, 2007; Franks et al., 2003; Nicholls et al., 2003). Hyaline
membrane formation is a hallmark of SARS-CoV lung damage in
humans (Hsiao et al., 2005). In addition to the hyaline membrane
formation in severe SARS cases, findings could include serous,
fibrinous, and hemorrhagic inflammation in pulmonary alveoli with
capillary engorgement, including micro-thrombosis in some of these
capillaries (Lang et al., 2003). Pulmonary alveoli are thickened with
interstitial mononuclear inflammatory infiltrates. Desquamation of
pneumocytes can be detected along with fibrinoid materials, and
erythrocytes in alveolar spaces (Lang et al., 2003). Cell types in the
respiratory tract in which SARS-CoV antigen has been detected
include the following: alveolar epithelial cells (primarily type II
pneumocytes), bronchial epithelial cells, and alveolar macrophages
(Ding et al., 2004; Ye et al., 2007). These cell types all have the
Table 1
Mortality, lung virus titer, and weight loss of 5- to 6-week-old BALB/c mice infected intranasally with the Urbani strain and two mouse-adapted strains of SARS-CoV.
SARS strain Inoculum
(~CCID50)
Survivors Mice losing
20% of weight
% Weight change
4 d.p.i.
Lung titer 3 d.p.i.
(Log CCID50/g)
Lung titer 6 d.p.i.
(Log CCID50/g)
v2163 105.5 0/10 10/10 −24±5.7 7.4±1.1 nta
v2163 104.5 2/10 10/10 −23±1.1 7.8±0.3 6.2±2.6
v2163 103.5 3/10 10/10 −24±4.9 7.9±0.3 7.3±0.6
MA15 105.5 7/10⁎⁎ 9/10 −22±8.3 6.6±0.3 nta
MA15 104.5 9/10⁎⁎ 8/10 −21±3.0 6.7±0.1⁎ 4.8±1.1b
MA15 103.5 10/10⁎⁎ 4/10 −19±3.3 6.9±0.2 6.3±0.7
Urbani 105.0 10/10 0/10 2.2±8.5 5.8±1.1 b3.8
Uninfected None 5/5 0/10 1.3±4.1 b3.8 b3.8
⁎Pb0.05, ⁎⁎Pb0.01 for MA15 compared with corresponding dilution of v2163.
a Not tested due to early death of v2163-infected mice at this virus concentration.
b Average contains one value below the limit of detection.angiotensin-converting enzyme 2 (ACE2), which has been identified
as one of the receptors to which SARS-CoV binds in order to be taken
up into host cells (Li et al., 2005a; 2003).
A number of animal species have been proposed to model SARS
infections in human, including macaques (Fouchier et al., 2003),
marmosets (Greenough et al., 2005), mice (Glass et al., 2004; Roberts
et al., 2005), golden Syrian hamsters (Roberts et al., 2006), rats
(Nagata et al., 2007), cats (Martina et al., 2003; van den Brand et al.,
2008), and ferrets (Chu et al., 2008; Martina et al., 2003; Subbarao and
Roberts, 2006; van den Brand et al., 2008). The utility of various
animal models has been extensively reviewed by Roberts and
Subbarao (2006). Briefly, the non-primate models do not exactly
model the lung pathology found in humans. For example, hyaline
membrane formation is not seen at all or rarely detected. In the rodent
models, fever is also not detected. Nevertheless rodent models may be
the most utile of the models because of low expense, ease of handling,
defined genetics, and the possibility of doing large-scale statistically
significant studies. Because of these advantages, a lethal rodent model
would be extremely valuable in antiviral drug testing where the
amounts of experimental compound available for evaluation in
animals are often limited.
Since early in the SARS outbreak, there has been a concerted effort
by many laboratories to evaluate vaccines (Du et al., 2009) or to
develop clinically approved drugs for efficacy against SARS-CoV to
rapidly provide a treatment for SARS infections in humans (Tong,
2009a,b). To date, there is no approved agent for treating SARS-CoV
and no agent has reached human clinical trials (Wong and Yuen,
2008). This is due to lack of animal model testing among other
reasons. Ribavirin had been used to treat SARS infections in 2003 and
2004, but its efficacy is questionable and it may exacerbate disease in
mice (Barnard et al., 2006b) and humans (Stockman, Bellamy, and
Garner, 2006). Wu and others have recently reviewed the state ofTable 2
Death and weight comparisons of 5- to 6-old week and 10- to 11-week-old BALB/c mice in
SARS strain Inoculum (~CCID50) 5- to 6-week-old mice
% Weight change (4 d.p.i.) Survival
v2163 105.5 −24±3.6 0/10
v2163 104.5 −23±3.8 1/10
v2163 103.5 −26±3.1 2/10
MA15 105.5 −25±3.5 8/10⁎
MA15 104.5 −28±1.6⁎⁎ 4/10
MA15 103.5 −23±3.4 10/10⁎⁎⁎
Urbani 105.0 −0.5±2.3 10/10
Uninfected None 0±2.4 5/5
⁎Pb0.05, ⁎⁎⁎Pb0.001 MA15 compared with corresponding dilution of v2163.
a Mean day of death; animals surviving to the end of the study were excluded.drug discovery for SARS-CoV antiviral agents (Pyrc, Berkhout, and van
der Hoek, 2007; Stockman, Bellamy, and Garner, 2006; Tong, 2009b;
Wu et al., 2006; Yeung and Meanwell, 2007). In the current study, we
report on the pathogenesis and genetic changes of a SARS-CoV strain,
called v2163, which was adapted from SARS-CoV Urbani by 25 serial
passages to cause a lethal pulmonary syndrome in 5- to 6-week-old
mice. Using multiple drugs with purported antiviral activity, the
utility of the new strain as a model virus for evaluating drugs in cell
culture and in mice is shown.
Results
Morbidity and virus titers in mice
The Urbani strain of SARS-CoV, which is not lethal to BALB/c mice,
was serially passaged 25 times in BALB/c mice at 3-day intervals and
resulted in a highly lethal strain we designated as v2163. The v2163
virus caused severe signs of illness in 5- to 6-week-old BALB/c mice
including ruffled fur and lethargy within 3–4 days and death by day 6.
Another lethal mouse-adapted strain designated as MA15 (Roberts et
al., 2007) was tested in parallel for comparison. Both mouse-adapted
strains caused substantial weight loss and produced high virus titers
in the lungs of infected mice (Table 1). In contrast, SARS-CoV strain
Urbani-infected mice had no significant weight loss compared with
uninfected controls, although they had moderate virus titers in the
lungs 3 days post-virus exposure as shown previously by Barnard et al.
(2006a,b). Lung virus titers at 3 days post-virus inoculation (d.p.i.)
were higher in v2163-infectedmice than inMA15-infectedmice. Lung
titers did not appear dependent on the level of virus inoculum, but did
differ depending on the virus strain. The v2163 virus and MA15 virus
persisted in the lungs for 6 days, while Urbani strain was below
detection limit by day 6.fected intranasally with v2163, MA15, or Urbani strains of SARS-CoV.
10- to 11-week-old mice
MDDa % Weight change (4 d.p.i.) Survival MDDa
4.5±0.7 −18±1.2 0/10 4.8±1.8
5.9±1.4 −17±5.0 1/10 5.7±1.0
6.4±1.9 −20±2.0 0/10 7.3±0.7
3.5±3.5 −22±2.1 1/10 6.8±1.4
13.5±6.9 −23±2.4⁎⁎⁎ 3/10 8.6±3.9
N/A −24±1.4⁎ 9/10⁎⁎⁎ 14 (n=1)
N/A −2.3±2.2 10/10 N/A
N/A −2.3±2.5 5/5 N/A
Fig. 1. Percent survival of 5- to 6-week-old BALB/c mice infected with SARS-CoV strains
Urbani, v2163, and MA15; totals from two experiments. ⁎⁎⁎Pb0.001 MA15 compared
with v2163.Mortality and recovery in mice
Infection with v2163 resulted in 100% of the 5- to 6-week-oldmice
losing 20% of their initial weight, and 70–100% of mice dying
depending on the infectious dose (Table 1). Nearly all MA15-infected
mice lost more than 20% of their initial weight when infected with
104.5 or 105.5 CCID50 (Table 1), confirming results observed in 6- to 8-
week-old mice by Roberts et al. (2007). However, the v2163 strain
killed more mice than strain MA15 regardless of the inoculum used
(Table 1). The v2163 virus was lethal at concentrations as low as 103.5
CCID50 per mouse. In a replicate experiment, results were similar to
those in Table 1, except 6 of 10 mice receiving 104.5 CCID50 of MA15
died (Table 2). However, the MA15-infected mice that died had a
mean day of death (MDD) of 13.5±6.9 days, compared with 5.9±1.4
MDD for the corresponding v2163-infected group (Table 2). Overall,
death of 6-week-old mice infected with v2163 was significantly
greater (Pb0.001) than MA15-infected mice (Fig. 1). Recovery from
severe illness wasmore likely for MA15-infectedmice than for v2163-
infected mice, and v2163 was lethal at a lower infectious dose. The
average LD50 for v2163 was 103.3±0.3 CCID50 per mouse. These data
were unique because, by special provision, animals were not
euthanized during severe illness but allowed to die or recover
spontaneously.Fig. 2. Mutations found in v2163 and MA15 mouse-adaptedAge variability
The animal experiment was repeated comparing 5- to 6-week-old
mice with 10- to 11-week-old mice (Table 2). The older mice infected
with MA15 lost more weight by 4 d.p.i. than corresponding v2163-
infected mice, and their MDD was 2–3 days later than v2163-infected
mice. Mortality in 10- to 11-week mice was high for both mouse-
adapted virus strains using 105.5 and 104.5 CCID50 inocula. However,
only 10% of theMA15-infectedmice receiving the 103.5 inoculum died,
while 100% of the corresponding v2163-infected mice died. No mice
died from Urbani infection. Interestingly, in one separate age
experiment, only 20% (2/10) of mice 3–4 weeks old died from a
104.0–4.5 CCID50 v2163 infection, while 100% of 7- to 8-week-old mice
died (data not shown). This supported the notion that SARS-CoV was
more lethal in older hosts.
Genome sequence
The v2163 virus had nine mutations, one of which affected two
reading frames, resulting in changes to 10 amino acid residues
compared with the wild-type Urbani. Four mutations occurred in the
spike protein (S) region (Fig. 2). A putative G-A mutation was
observed in base pair 22722with some replicates, but it was not found
in RNA from infected mouse lungs. The mutations were compared to
the MA15 lethal strain (Roberts et al., 2007), revealing interesting
similarities and differences in the mutation spectra associated with
mouse adaptation in young BALB/c mice (Fig. 2). In the structural
genes, the Y436H mutation in the v2163 spike region was conserved
in strain MA15, and the M mutation was in a similar location on both
lethal strains (S6L for v2163, E11K in MA15). In the replicase genes,
the nsp9 mutation (E4185D) was located near an nsp9 mutation
(T4184A) found in strain MA15, and both lethal strains had an nsp13
mutation.
Cytokines and chemokines
The mouse-adapted strains of SARS-CoV elicited expression of
cytokines IL-1α and IL-6, and chemokines MIP-1α, MCP-1, and
RANTES in the lungs of mice 3 days after infection as measured with
the multiplex ELISA assay (Fig. 3). Levels of IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-9, IL-10, TNF-α, and GM-CSF were below the minimum detection
level for all test groups (≤38 pg/mL of lung homogenate). Low levels
of IFN-γ were observed with both mouse-adapted strains but not
detected with the Urbani strain. Two out of 10 v2163-inoculated mice
showed low cytokine response, and were excluded from cytokine
analysis because they also had little or no virus detected in their lungs.strains of SARS-CoV compared with the Urbani strain.
Fig. 3. Average cytokines detected in BALB/c mice lungs 3 days after infection with various strains of SARS-CoV (n≥8). Black bars are v2163, gray bars are MA15, striped bars are
Urbani, and white bars are uninfected controls. ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 MA15 compared with Urbani. aLower limit of detection. bThe v2163 and MA15 averages included
some extrapolated values that were minimum estimates.
Fig. 4. Histological slides showing representative lung pathology. (a) Urbani-infected lung with no significant changes (40×). (b) MA15-infected lung with small numbers of foamy
macrophages that widen scattered alveolar septae (40×). (c)MA15-infected lungwith rare individual bronchiolar lining cells that were swollen and hypereosinophilic, and scattered
alveolar septae widened by foamymacrophages (40×). (d) v2163-infected lung with moderate numbers of neutrophils and edema fluid surrounding several large vessels (40×). (e)
v2163-infected lung with small numbers of alveolar macrophages throughout airspaces (60×). (f) Uninfected lung with no significant changes (40×).
Table 3
Survival, mean day of death, lung scores, weight change, and virus titers in BALB/c mice infected with mouse-adapted SARS-CoV v2163 and treated with ribavirin, UDA, EP128533, or
Ampligen™.
Treatment Survivors/total Mean day of
death±SD
Lung score
6 d.p.i.
Weight change
(g)a
Lung titer 3 d.p.i.
(Log CCID50/g)
Lung titer 6 d.p.i.
(Log CCID50/g)
Normal saline 0/10 6.2±1.7 3.2±0.58 −2.8±0.40 7.0±0.11 5.9±1.4
Ribavirin (75 mg/kg/day) 3/10 4.5±0.84⁎ 2.5±0.94 −2.0±0.07⁎ 7.0±0.24 7.0±0.82
Ampligen™ (10 mg/kg/day) 10/10⁎⁎⁎ N14⁎⁎⁎ 0.90±0.89⁎ 0.40±0.14⁎⁎⁎ 7.6±0.52 4.3±0.16
UDAb (5 mg/kg/day) 5/10⁎ 6.6±2.0 2.17± 0.29 −2.3±0.14 7.32±.07 6.6±0.93
Cremaphorc 1/15 4.3±1.3 NT −2.6±0.35 8.1±0.23 NT
EP128533c (30 mg/kg/day) 0/10 4.5±1.4 NT −3.2±0.28 8.2±0.14 NT
⁎Pb0.05, ⁎⁎⁎Pb0.001 compared with saline or cremaphor control.
NT=not tested, all mice died before day 6.
a Mean weight difference evaluated on day 3 post-virus exposure.
b Separate experiment with 10-day duration versus normal 14 days.
c Separate experiment with 10% cremaphor as diluent instead of saline.The MA15 virus stimulated significantly more MIP-1α and RANTES
compared with Urbani (Pb0.05), and the v2163 virus caused
significantly greater MCP-1 response than Urbani (Pb0.01). A
significantly higher IL-6 response compared with the wild-type
Urbani strain was observed from both v2163 and MA15 mouse-
adapted strains (Pb0.001 and Pb0.05, respectively). The v2163-
infected mice expressed 6-fold more IL-6 than the MA15-infected
mice. At the infection level used in this experiment, 100% of v2163-
infected mice died and no MA15-infected mice died, showing a
correlation between IL-6 concentrations in the lungs and mortality.
Histopathology
Three lung samples for each virus or control were evaluated for
pathological changes 3 days after inoculation by a board certified
veterinary pathologist (Fig. 4). Lungs of mice inoculated with the
Urbani strain of SARS-CoV showed no significant changes, and sham-
infected controls showed no marked changes except some scattered
dense granulomas in one of three lungs. All three MA15-infected
lungs showed small numbers of foamy macrophages and small
numbers of neutrophils. Alveolar septae were seen in two of the three
MA15-infected lungs. One MA15-infected lung had rare individual
bronchiolar lining cells that were swollen and hypereosinophilic and
degenerate. Pathological changes were observed in two of the three
v2163-infected lungs; one had moderate numbers of neutrophils,
edema fluid surrounding several large vessels, and rare granulomasTable 4
Lung IL-6 levels, virus titer, and pathology in BALB/c mice 3 and 6 days after infection with
Treatment Daya IL-6 (pg/mL) Lung titer (Log CCID50/g)
Saline, uninfected 3 2200±670 b2.8
Saline 3 3880±2210 7.7±0.63
Ribavirin (75 mg/kg/day) 3 2230±610⁎ 7.7±0.21
Ampligen™ (10 mg/kg/day) 3 1650±580⁎ 8.0±0.39
UDA (5 mg/kg/day) 3 3330±1340 7.9±0.84
EP128533 (30 mg/kg/day) 3 4690±1520 8.2±0.14
Cremaphor control 3 5000±1990 8.1±0.23
Saline control 6 2140±560 6.8±0.85
Ribavirin (75 mg/kg/day) 6 2320±820 5.0±1.7
Ampligen™ (10 mg/kg/day) 6 1590±380 6.2±1.5
UDA (5 mg/kg/day) 6 2530±1760 7.0±0.32
EP128533 (30 mg/kg/day) 6 nt nt
Cremaphor control 6 nt nt
⁎Pb0.05, compared to untreated control (excluding 655 pg/mL outlier in PSS day 3).
nt=not tested because all mice from this group died before day 6.
a Days post-inoculation.
b Small to moderate numbers of neutrophils in alveoli or surrounding scattered vessels.
c Small to moderate numbers of histiocytes in alveoli.
d Widened groups of alveolar septae.
e Terminal bronchioles contain luminal degenerate and necrotic cellular debris, or are lincontaining refractile central fragments of foreign material replacing
groups of alveoli. Another v2163-infected lung showed small
numbers of alveolar macrophages throughout airspaces. In general,
lungs infected with MA15 or v2163 showed acute to subacute
alveolitis with some perivascular edema in some sections (Fig. 4).
Differences between the two mouse-adapted strains were minimal.
Hyaline membrane formation, as occurs in human SARS patients
(Roberts et al., 2005), was not observed.In vivo efficacy of drugs against v2163 infection
To demonstrate the utility of the lethal mouse model for antiviral
drug testing, we evaluated the known antiviral agents ribavirin, an
antiviral nucleoside analog (Sidwell et al., 1972), and Ampligen™
(poly I:poly C12U), a synthetic dsRNA polymer that induces interferon
production (Barnard et al., 2006a; Carter et al., 1972; Gowen et al.,
2007). We also evaluated the novel drugs EP128533, a dipeptidyl
glutaminyl fluoromethylketone protease inhibitor (Zhang et al.,
2006), and UDA, a lectin that impedes viral fusion and egress
(Keyaerts et al., 2007). Ampligen™ (10 mg/kg/day) afforded mice
complete protection against death, reduced virus titers in the lungs,
and significantly reduced lung scores and weight loss (Table 3). UDA
treatment of 5mg/kg/day resulted in 50% protection from death up to
10 days after infection (Table 3), but no reduction in lung virus titer. A
replicate 21-day study showed 40% protection and no measurableSARS-CoV strain v2163 and treatment with Ampligen™, ribavirin, UDA, or EP128533.
Summary of histopathology (inclusive)
Neutrophilsb Histiocytesc Widened alveolid Degenerate/necrotice
0 0 0 0
3 3 2 3
2 2 2 1
3 3 3 0
3 3 3 2
0 1 0 1
1 1 1 1
2 2 1 0
0 2 0 0
3 3 3 0
3 3 3 0
nt nt nt nt
nt nt nt nt
ed by individual degenerate or necrotic epithelial cells and/or necrotic cell debris
Fig. 5. Effects of Ampligen™ , ribavirin, EP128533, and UDA on survival of BALB/c mice
infected with SARS-CoV strain v2163.toxicity with 15 mg/kg/day of UDA (data not shown). Protease
EP128533 was inactive in BALB/c mice.
Ribavirin treatment of 75 mg/kg/day did not significantly protect
mice from death (Table 3). Virus lung titers from mice treated with
ribavirin were no different than those detected from control mice on 3
d.p.i., but at 6 d.p.i. the titers in ribavirin-treated mice were higher
than those detected in the control group, suggesting that ribavirin
prolonged lung infection, although this difference was not statistically
significant (Table 3). Gross pathology (lung scores) at day 6 revealed
substantial lung discoloration in ribavirin-treated mice. The MDD in
mice treated with ribavirin was reduced (Table 3), but the survivor
curve was statistically similar to that of PSS controls (Fig. 5). In the
second experiment, virus titers were lower than controls in ribavirin-
treatedmice on day 6 (Table 4), but 50% of that group also died by 6 d.
p.i. (data not shown).
The IL-6 concentration in the lungs on3d.p.i.was significantly lower
(Pb0.05) in mice receiving Ampligen™ or ribavirin treatment, andTable 5
In vitro antiviral activity of various compounds in vitro against SARS-CoV Urbani and a mo
Virus strain Compound Inoculuma Visual assay
EC50b (μg/mL) IC50c (μg/mL)
v2163 Ribavirin 102.2 66±43 N1000
Urbani Ribavirin 101.9 63±36 N1000
v2163 Promazine 102.2 2.6±1.1 6.4±2.3
Urbani Promazine 101.9 2.1±1.0 7.9±3.4
v2163 Calpain VI inhibitor 102.2 14±5.4 N37
Urbani Calpain VI inhibitor 101.9 13±2.9f N37
v2163 Calpain IV inhibitor 102.2 4.1±3.5 N56
Urbani Calpain IV inhibitor 101.9 0.87±0.13 N56
v2163 Infergen™ 101.9 b0.00012 N0.32
Urbani Infergen™ 101.6 b0.00029 N0.32
v2163 Ampligen™ 101.7 N240 N240
Urbani Ampligen™ 101.7 N240 N240
v2163 UDA 101.7 0.70±0.22 N10
Urbani UDA 101.7 0.62±0.26 N10
v2163 EP128533 102.0 1.4±1.1 N100
Urbani EP128533 101.8 0.56±0.57 N100
a Average CCID50 virus per well from three replicates.
b 50% effective antiviral concentration.
c 50% cell inhibitory concentration of drug without virus.
d In vitro 90% effective antiviral concentration by virus yield assay.
e Selective index: SI=IC50/EC50, and virus yield SI=IC50/EC90.
f Two replicates only.slightly lower with UDA compared with controls (Table 4). EP128533-
treatedmice showed no difference in IL-6 compared with controls. The
uninfected control group had IL-6 levels of 2200± 670 pg/mL, which
could be a result of stress induced by handling mice during daily
weights and twice daily treatments. Therefore, 2200 pg/mL was
considered the baseline IL-6 concentration in this study.
Histopathology of mice with varied antiviral treatments showed
neutrophil infiltration and degenerate cells (Table 4). Lesions
observed by a board certified pathologist were summarized in tabular
form, and all lesions observed were included. Lungs in mice treated
with a protease inhibitor, EP128533, and cremaphor solvent control
appeared to have less overall lesions on 3 d.p.i. than lungs of mice in
other treatment groups. Ribavirin-treated lungs had fewer overall
lesions than those of other groups on 6 d.p.i. Macrophage infiltration,
lymphocyte infiltration, and edema were not detected in infected
lungs in this experiment, and no hyaline membrane formation was
observed. Histological changes were similar between Ampligen™
treated groups and untreated control groups (Table 4).
In vitro efficacy testing with strain v2163
The v2163 strain was tested in vitro for sensitivity to multiple
antiviral compounds. Compounds were chosen based on their mode
of action or purported activity in previous literature. Vero-76 cells
were treated with multiple concentrations of each compound then
infected with virus, and the 50% effective concentration (EC50), the
50% cytotoxic concentration (IC50), and the selective index (SI) for
each compound were calculated (Table 5). Compounds with a high
selective index were considered active. The antiviral activity of drugs
against v2163 was similar to that of the same compounds against the
Urbani strain (PN0.05). Infergen™ , a consensus interferon-α
(Kumaki et al., 2008), was shown to be highly active, with a 90%
effective concentration of b0.65 μg/mL against both strains and SI
values N490. Ribavirin, promazine, an antipsychotic drug (Barnard et
al., 2008), and calpain inhibitor VI (Barnard et al., 2004) showed no
appreciable activity above their cytotoxic concentration (Table 5).
EP128533 (Zhang et al., 2006) and UDA were moderately active.
Calpain inhibitor IV (Barnard et al., 2004) was slightly active against
both SARS-CoV v2163 and Urbani strains, with a 90% effective
concentration of 12 and 6.4 μg/mL and SI values of 3.9 and 8.1,
respectively. The v2163 strain appeared less sensitive to calpainuse-adapted strain of SARS-CoV.
Neutral red assay Virus yield reduction
SI EC50 (μg/mL) IC50 (μg/mL) SI EC90d (μg/mL) SIe
15 80±74 200±92 2.5 83±63 2.4
16 86±50 99±51 1.7 104±84 1.4
2.5 8.0±7.2 7.3±4.2 0 3.9±2.2 1.9
3.8 3.4±2.1 8.1±3.0 2.4 3.1±2.1 2.6
2.6 17±7.3 37±5.1 2.1 24±7.9f 1.5
2.8 14±10f 27±4.4 1.9 15±1.0f 1.7
14 9.5±9.2 48±19 5.1 12±2.6f 3.9
64 4.3±4.5 52±18 12 6.4±2.6f 8.1
N2700 b0.00011 N0.32 N2800 b0.00065 N490
N1100 b0.31 N0.32 N1000 b0.65 N490
1.0 N240 N240 1.0 N240 1.0
1.0 N240 N240 1.0 N240 1.0
14 0.86±0.39 21±9.5 24 1.1±19 19
16 0.76±0.22 21±9.5 27 0.95±0.36 22
N71 1.6±1.6 N100 N61 12±9.4 N8.5
N180 1.3±2.1 N100 N75 5.3±3.7 N19
Table 6
Cytokine responses during SARS-CoV infection of lethally-infected mice compared to
humans with SARS disease.
Cytokine Lungs of lethally-
infected mice
Human lungsa
(number of studies)
Human serumb (number
of studies reviewed)
IL-1α + ND ND
IL-1β 0 0 (1) 0 (2)
+ (3)
IL-2 0 0 (1) 0 (5)
+ (2)
IL-3 0 ND ND
IL-4 0 0 (1) 0 (5)
IL-5 0 ND ND
IL-6 + + (1) 0 (2)
+ (6)
IL-9 0 ND ND
IL-10 0 0 (1) 0 (6)
+ (1)
IFN-γ + 0 (1) 0 (2)
+ (4)
TNF-α 0 0 (1) 0 (7)
+ (3)
GM-CSF 0 ND ND
MCP-1 + + (1) 0 (1)
+ (4)
MIP-1α + ND ND
RANTES + ND 0 (4)
IP-10 +c + (2) + (5)
+=cytokine elevated, 0=cytokine not elevated, ND=not determined.
a Source: Chen and Subbarao (2007).
b Sources: Hsueh et al. (2004); Cameron et al. (2008); review of Chen and Subbarao
(2007); review of Zhu (2004).
c Separate study currently in press.inhibitor IV and EP128533 than strain Urbani, although the differ-
ences were not statistically significant.
Discussion
We have developed a newmouse-adapted strain called v2163 that
causes increased morbidity and mortality in BALB/c mice, which the
parent Urbani strain does not do. Strain v2163 was derived from the
Urbani strain of SARS-CoV by serial passage in BALB/c mice. Mice
infected with the v2163 strain were less likely to survive SARS-CoV
infection than Urbani-infected or MA15-infected mice. The MA15
strain appeared less lethal in the current study than shown by Roberts
et al. (2007). However, in the study previously reported, death was
based on 20% weight loss. When 20% weight loss was equated to
mortality in the current work, the results for MA15 were closely
similar to previous reports (Table 1). Further, the prior finding that an
inoculum of 103.9 CCID50 of MA15 per mouse was sublethal (Roberts
et al., 2007) was confirmed in the current work. The reduced lethality
of strain MA15 in the current experiments may also be attributed to
the use of 5- to 6-week-oldmice rather than 6- to 8-week-oldmice. In
the current study, 5- to 6-week-old mice were much less susceptible
to MA15 than were 10- to 11-week-old mice (Table 2). SARS-CoV is
known to be more fatal in aged patients than in younger patients
(Chen and Subbarao, 2007). Age-related susceptibility to SARS-CoV in
mice has been shown previously with 4-week-old versus 6-month-
old mice (Nagata et al., 2008), with 12- to 14-month-old mice
(Roberts et al., 2005), and between 10-week-old and 1-year-old mice
(Rockx et al., 2007). The lethality of the v2163 virus in younger mice is
an advantage for its use as a convenient model for evaluation of
potential antiviral treatments.
The v2163 genome contained nine mutations compared with the
parent Urbani strain, and these resulted in 10 amino acid residue
changes since bp 26133 affects two reading frames. Although the v2163
strainwas developed independently, its genome sharedmutationswith
the previously created mouse-adapted MA15 strain (Fig. 2). The spike
mutation Y436H was common to both lethal strains, and is within the
receptor-binding motif (Roberts et al., 2007). The Y436H mutation has
been shown to enhance infectivity of recombinant viruses in mice
(Becker et al., 2008), presumably by providing a more favorable
interaction with the mACE2 receptor for docking and entry. The
v2163 strain had three mutations in the S (spike) region that were
not present in MA15, suggesting that the increased virulence observed
with v2163 potentially may be due to binding properties. Moreover,
Y442F is a contact interface residue site that engages the ACE2 receptor,
and passage of civet strain SZ16 K479N in human airway epithelial cells
selected for a similar change at this position, shown to enhance SZ16 S
interaction with the hACE2 receptor (Sheahan et al., 2008). Further, in
separate work, a Y442L mutation was seen on a third mouse-adapted
strain (MA20) in the same amino acid residue as the Y442Fmutation of
v2163 (Frieman et al., publication in preparation). Interestingly, the
T1181L and N1169D alterations are in the heptad repeat elements in S2
where they could promote fusion and entry or host range expansion
(McRoy and Baric, 2008).
Mutations outside of the spike region also appeared to be
important. The mutation in the M glycoprotein gene (S6L) is near
the MA15 E11K mutation that has been associated with increased
production of virus particles from infected cells, presumably by
promoting more efficient assembly and release, although the exact
mechanism is unknown (Pacciarini et al., 2008). The nsp9 E4185D
mutation is located near the nsp9 T4184A mutation of MA15, and
likely confers a similar phenotypic difference, presumably increasing
virulence. Both lethal strains had an nsp13 mutation, although it is
not known if they confer similar changes to the protein structure.
The fact that independent selections resulted in similar mutation
profiles in target genes supports their role in increased replication
and/or pathogenesis. Elucidation of the effects of these specificmutations may be key to understanding the genotypic variations that
lead to more lethal phenotypes of SARS-CoV and coronaviruses in
general. Such knowledge could allow rapid synthesis of chimeric
viruses for use in evaluating and developing effective antiviral
treatments.
Multiple cytokines and chemokines expressed in the lungs of
BALB/c mice 3 d.p.i. infected with mouse-adapted SARS-CoV were
significantly higher than those found in lungs of mice infected with
the Urbani strain of SARS-CoV (Fig. 3). IL-6 and MCP-1 were more
strongly expressed in v2163-infected mice than in MA15-infected
mice. IL-6 and MCP-1 have been observed in human SARS patients
(Chen and Subbarao, 2007), and one human study determined that IL-
6, IL-8, and MCP-1 indicated a high risk of death (Jiang et al., 2005).
Therefore, MCP-1 and IL-6 are likely good early indicators of disease
outcome in mice. In contrast, cytokines MIP-1α and RANTES were
more elevated in MA15-infected groups than v2163-infected groups.
Since MA15-infected mice had lower mortality than v2163-infected
mice, MIP-1α and RANTES may not be good indicators of disease
outcome. When comparing the mouse cytokine profile to that
detected in human SARS patients, the majority of human studies
showed the same profile as seen in mice for IL-2, IL-4, IL-6, IL-10, IFN-
γ, TNF-α, IP-10, andMCP-1 (Cameron et al., 2008; Chen and Subbarao,
2007; Hsueh et al., 2004; Zhu, 2004) (Table 6). In contrast, IL-1β was
not elevated in mouse lungs or in human lungs, but with serum three
of five studies reviewed showed elevated IL-1β in human patients.
RANTES was elevated in mouse lungs but not in the human sera.
However, uninfected controls had elevated RANTES levels in mice as
well, so the response was not considered important. IFN-γ was
detected in lethally infected mouse lungs but not in human lungs.
Nevertheless, the IFN- γ findings were considered consistent with
human data since the IFN-γ level in mice was low, and IFN-γ has been
found in human serum in some studies but not others. The two
mouse-adapted SARS-CoV strains in this study both resulted in similar
cytokine profiles (Fig. 3).
IL-6 levels were of particular interest. The increase in IL-6
corresponded directly with an increase in mortality in the respective
experimental groups. Mice infected with the wild-type Urbani strain
showed no signs of disease or death, and they had no IL-6 detected in
the lungs, while v2163-infected mice expressed high levels of IL-6. In
one replicate study, 100% of v2163-infected mice died, and the
average IL-6 level for lung homogenates in that group was 2750 pg/
mL with only one mouse lower than 2700 pg/mL. The corresponding
MA15-infected group in the same study had 100% recovery after
severe illness, and those mice had an average IL-6 concentration of
only 520 pg/mLwith no sample higher than 900 pg/mL. Similarly, one
clinical study found that patients with the poorest outcomes also had
high levels of IL-6 secreting cells (Jones et al., 2004). In the current
work, infected mice receiving PSS, cremaphor, and EP128533 groups
showed higher IL-6 concentrations than the ribavirin, Ampligen™,
and UDA groups (Table 4). The lower IL-6 concentration on 3 d.p.i.
coincided with treatments that afforded at least some protection
against death in the survival study (Table 3).
The role of IL-6 in SARS-CoV infection merits further investigation.
IL-6 is critical in B-cell maturation and acute-phase responses (Kopf et
al., 1994), and it is critical in coordination of immune response
(Gowen et al., 2006). Conversely, a study reported by Hegde, Pahne,
and Smola-Hess (2004) suggests that IL-6 also has immunosuppres-
sive properties. However, high expression of IL-6 may exacerbate
disease. In SARS patients, damage to the lung seems to be primarily by
viral destruction of alveolar and bronchial epithelial cells and
macrophages (Chen and Subbarao, 2007). However, elevated IL-6
levels and concomitant lung damage continued even after peak virus
production, which suggests that IL-6 contributes to disease progres-
sion (Wang et al., 2004). Furthermore, a SARS patient study showed
altered liver function, leucopenia, lymphopenia, thrombocytopenia,
and subsequent respiratory distress syndrome, suggesting that there
was inflammatory damage resulting from SARS-CoV infection (Peiris
et al., 2003a). Studies with other viruses also suggest that excess
production of IL-6 may exacerbate disease. For example, a study of
herpes simplex virus (HSV) suggested that exuberant production of
IL-6 in neonates may explain why sepsis syndrome is more common
with HSV infection in neonates than in adults (Kurt-Jones et al., 2005).
A study of phlebovirus infection also proposed that IL-6 contributes to
pathogenesis (Gowen et al., 2006). Regardless of the cause–effect
relationship, we found that IL-6 is strongly expressed in the lungs
during infection with mouse-adapted SARS-CoV virus and may be an
effective predictor of disease outcome.
The histopathology of SARS is difficult to distinguish because most
lesions observed with SARS can be found with many infections. The
main distinguishing histopathological factors in human SARS disease
are consolidation, edema, and hyaline membrane formation (Guo et
al., 2008). Also, inflammatory infiltrates, usually composed of mostly
macrophages and lymphocytes, are disproportionately low in number
with respect to the alveolar damage, and sometimes absent (Chen and
Subbarao, 2007; Cheung et al., 2004; Guo et al., 2008). In the current
study, lungs infected with mouse-adapted strains of SARS-CoV
showed acute to subacute alveolitis with some perivascular edema
in some sections. Mice lungs had slight to moderate neutrophil and
macrophage infiltration, but lymphocytes were not observed. Eryth-
rocyte infiltration and some fibrinous material were observed with
v2163 in some experiments not shown. No hyaline membrane was
formed in themouse lungs. Since lung pathology differed from human
disease, and since mice groups that died from infection had similar
pathology to that of treated mice that survived infection (Tables 3 and
4), we submit that histopathology will not be an important marker in
this SARS model.
SARS infects multiple tissues in humans, including spleen,
intestines, kidneys, liver, adrenal, parathyroid, pituitary, cerebrum,
and pancreas and neurons of CNS (Chen and Subbarao, 2007; Guo et
al., 2008). With v2163, infectious virus was consistently found in the
lung and snout of v2163 inoculated mice on days 3 and 6 post-
inoculation, but was only rarely seen in serum. Virus was notrecovered from kidney, brain, spleen, intestine, liver, or heart of
v2163-infected mice with limits of detection of 2.1 log CCID50 for
kidney; 1.1 log CCID50 for brain, spleen, and heart; and 4.1 log CCID50
for liver and intestine (data not shown). With MA15, Roberts et al.
(2007) reported low titers of infectious virus found in lung, brain,
spleen, and liver of mice infected with MA15.
Ribavirin, Ampligen™, EP128533, and UDA treatments were
selected to assess the new v2163 strain of SARS-CoV as a model for
in vivo evaluation of potential antiviral drugs. These drugs where
chosen to represent a variety of modes of action.
Ribavirin is a known antiviral compound (Sidwell et al., 1972) with
multiple modes of action, most of which stem from inhibition of
inosine monophosphate dehydrogenase (IMPDH) leading to de-
pressed intracellular GTP levels (Streeter et al., 1973). We had
previously found in a mouse virus lung replicationmodel of SARS-CoV
that ribavirin extended the time that virus could be detected in the
lungs of mice (Barnard et al., 2006b), and this was also observed in
one trial of the current study (Table 3). The prolonged high lung titers
observed suggested that ribavirin may contribute to the pathogenesis
of SARS-CoV by prolonging and/or enhancing viral replication in the
lungs, allowing continual stimulation of the inflammatory response,
which may contribute to pathogenesis (Perlman and Dandekar,
2005). Also, ribavirin is known to be somewhat toxic, causing
hemolytic anemia and other adverse side effects (Wong and Yuen,
2008), so ribavirinwould presumably exacerbate disease if therewere
no concomitant antiviral effect. Interestingly, exacerbation of viral
disease by ribavirin has also been shown with West Nile virus,
resulting in increased mortality in hamsters (Morrey et al., 2004) and
possibly in human patients (Chowers et al., 2001). In contrast, the
second experiment in the current work showed significantly
decreased IL-6 concentrations on 3 d.p.i. and somewhat decreased
virus titers in ribavirin-treated animals on 6 d.p.i., suggesting some
effect of ribavirin in mice (Table 4). The IL-6 reduction with ribavirin
was interesting in light of previous reports that ribavirin inhibited IL-6
production in respiratory epithelia cells infectedwith RSV virus (Jiang,
Kunimoto, and Patel, 1998) and endothelial cells infectedwith dengue
virus (Huang et al., 2000). However, IL-6 was not reduced by ribavirin
in activated T-cells (Hultgren et al., 1998), and ribavirin treatment did
not reduce SARS-CoV viral load or IL-6 in human SARS patients (Wang
et al., 2005). Ribavirin has not been shown to be effective against SARS
in humans. In 2006, systematic review and comprehensive summary
of treatments used for SARS patients found that 26 studies with
ribavirin were inconclusive and that four showed possible harm
(Stockman, Bellamy, and Garner, 2006). However, a 2008 review
stated that ribavirin treatment combined with protease inhibitors
could be useful clinically, although randomized controlled trials were
still needed (Wong and Yuen, 2008). Another study showed synergy
with ribavirin in combination with IFN-β in vitro (Morgenstern et al.,
2005). Additional research is required to draw more certain conclu-
sions about ribavirin in mice, including age-related studies and drug
combination experiments using the lethal v2163 virus as a model.
Ampligen™, poly(I:C(12)U), is a synthetic dsRNA polymer that
stimulates production of interferon (Carter et al., 1972; Gowen et al.,
2007). Ampligen™ has been shown to be effective in vivo against
multiple viruses, including Coxsackie virus (Padalko et al., 2004),
Venezuelan equine encephalitis (VEE) virus (Julander et al., 2008),
punta toro virus (Sidwell et al., 1994), Modoc virus (Leyssen et al.,
2003), duck hepatitis B virus (Niu et al., 1993), Banzi virus (Pinto,
Morahan, and Brinton, 1988), herpes simplex type 2 (HSV-2) virus
(Pinto, Morahan, and Brinton, 1988), and Pichinde virus (Smee et al.,
1993). In a virus replication model, Ampligen™ at 10 mg/kg was
previously found to afford protection against SARS-CoV replication in
the lungs (Barnard et al., 2006a). SARS-CoV is known to be sensitive to
type I interferons, IFN-α/β (Cinatl et al., 2003; Stroher et al., 2004).
Normally, in the presence of double-stranded RNA or 5′-tripho-
sphorylated ssRNA such as in viral infection, IFNs are synthesized and
secreted by infected cells and stimulate expression of potent antiviral
proteins (Sadler and Williams, 2008; Samuel, 2001). However, IFN
pathways are blocked in cells infected with SARS-CoV (Frieman,
Heise, and Baric, 2008), thus making the host more susceptible to
infection. We believe that exogenous stimulation of IFN pathways
with Ampligen™ overcomes the evasion of virus sensing and signaling
pathways. Furthermore, Kuri et al. (2009) suggested that “priming”
with small amounts of IFN helps the cells themselves restore their
normal IFN response to SARS-CoV. In the current study, Ampligen™
appeared not to affect virus replication initially, but led to more
rapid decline of virus in the lungs compared with untreated animals
by 6 d.p.i. (Table 3). The study showed that Ampligen™ protected
against death and gross damage to the lungs in the presence of lethal
SARS-CoV.
Stinging nettle lectin (Urtica doica agglutinin, UDA) is an N-acetyl
glucosamine-specific lectin that was reported as efficacious against
HIV (De Clercq, 2000). More recently, UDA was reported to inhibit
coronaviruses in vitro with some selectivity (van der Meer et al.,
2007a). Keyaerts et al. (2007) showed that UDA was a potent and
selective inhibitor of SARS-CoV strain Frankfurt-1. Plant lectins like
UDA probably target viral attachment and fusion, and exocytosis or
egress of the virus from the cell (Balzarini, 2007; van der Meer et al.,
2007b; Keyaerts et al., 2007). The reduction of IL-6 in lungs at 3 d.p.i.
along with 50% survival of mice in this study provide evidence to
support further investigation of UDA treatment regimens as potential
antiviral therapies.
Zhang et al. (2006) reported the design and synthesis of a SARS-
CoV protease inhibitor EP128533, 4-(Z-Val-amido)-6-fluoro-5-oxo-
hexanoic acid dimethylamide, chemical formula C21H30FN3O5 and
molecular weight 423. It was shown to inhibit replication of SARS-CoV
strains FFM1 and 6109 in Vero and CaCo2 cells. In the current study,
EP128533 was active in cell culture against the Urbani and v2163
strains of SARS-CoV (Table 5), but it was not efficacious in preventing
death or reducing the disease signs measured in BALB/c mice (Tables
3 and 4). Since EP128533 is relatively insoluble, the lack of activity is
likely because it is not bioavailable in the animal. EP128533 in
uninfected mice was not toxic, and replicate trials using DMSO as the
solvent yielded similar results as with cremaphor (data not shown).
Nevertheless, based on in vitro results, this compound may be a
foundation for an effective antiviral protease if a prodrug is developed
to make it more soluble and bioavailable.
In vitro sensitivity to antiviral compounds of the v2163 strain was
similar to that of strain Urbani (PN0.05) when the two strains were
tested in parallel against multiple compounds. In vitro data confirmed
recent findings by Barnard et al. (2006b, 2008) that promazine, an
antipsychotic drug, and ribavirin, a nucleoside analog, were not
effective against SARS-CoV in vitro. Findings with v2163 supported
prior findings that Infergen™ was active in vitro against SARS-CoV
Urbani (Kumaki et al., 2008). Protease inhibitor EP128533 was active
in vitro, as shown previously (Zhang et al., 2006). The current in vitro
results showed no marked activity with a calpain inhibitor VI, and
slight to moderate activity with calpain inhibitor IV. A previous report
showed greater antiviral activity with calpain inhibitor VI than with
calpain inhibitor IV (Barnard et al., 2004), and the differences were
attributed to greater cell sensitivity to drug toxicity in the previous
work, inoculum variation between studies, and stronger virus
replication in mammalian cell culture during the current study. UDA
was found to be moderately active with antiviral selectivity (SI=19–
22), as with previous work (Keyaerts et al., 2007). Therefore, the
v2163 strain was shown to be effective for evaluating antiviral
compounds in vitro using microscopic cytopathic effect, neutral red
assays, and virus yield reduction tests. Using the v2163 strain in
various in vitro assays allowed detection of a highly active compound
and various inactive compounds. This will facilitate future analysis of
antiviral compounds, since they can be screened in vitro with the
v2163 strain and tested in vivo with the same strain.In conclusion, the new v2163 mouse-adapted strain of SARS-CoV
was highly virulent in BALB/c mice 5–6 weeks old, even with
infectious doses as low as 103.5 CCID50 per mouse. Infection with
v2163 caused signs of disease, a strong immunological response, and
lung pathology. The v2163 infection largely simulated human disease,
except that hyaline membrane formation was not detected in the
lungs, and infectious virus was not found in tissues outside of the
respiratory tract, as is characteristic in human infection (Chen and
Subbarao, 2007). Mutations in the virus were consistent with those
seen in another mouse-adapted strain, and these may be useful in
identifying genotypic markers for lethality. The v2163 strain propa-
gated well in cell culture and was shown to be suitable for in vitro
screening of potential antiviral compounds against SARS-CoV. Strain
v2163 was used effectively as an in vivo model to evaluate SARS-CoV
therapies, showing that Ampligen™ pretreatment was active against
lethal SARS-CoV infection, and that UDA may have antiviral effects as
well. This new model will facilitate identification of valuable antiviral
compounds against SARS-CoV and against future emerging pathogens
related to SARS-CoV.
Materials and methods
Mice, cells, and media
Female BALB/c mice were obtained from Charles River Laborato-
ries (Wilmington, MA). They weremaintained onWayne Lab Blox and
tap water ad libitum. They were quarantined for N24 h prior to use.
Cells used were Vero-76 (ATCC CRL1587), Vero-E6 (ATCC CRL1586),
and Vero (ATCC CCL81) maintained in MEM supplemented with 10%
fetal bovine serum (FBS) and no antibiotics. For virus titer tests, MEM
with 2% FBS and 50 μg/mL gentamicin was used.
Test compounds
Ribavirin was provided by ICN Pharmaceuticals (Costa Mesa, CA).
Calpain inhibitor IV and calpain inhibitor VI were obtained from
CalBiochem (San Diego, CA). Infergen™ was interferon alfacon-1 lot
002586 kindly provided by Intermune, Inc. (Brisbane, CA) in 27 μg/mL
solution and held frozen until tested. Ampligen™ from Hemispherx
Biopharma, Inc. was obtained through the NIAID Antiviral Substances
Program. Promazine HCl was obtained from Sigma Chemical Corpora-
tion (St. Louis, MO). EP128533 was obtained from Epicept Corporation
(San Diego, CA) and through the NIAID Antiviral Substances Program.
Stinging nettle lectin (UDA) was obtained from EY Laboratories, Inc.
(San Mateo, CA). Compounds were suspended in DMSO or purified
water at 20 mM, then diluted in minimal essential medium (MEM) as
needed for in vitro assays. Compounds for in vivo assayswere diluted in
saline, except protease inhibitor EP128533, which was diluted in a
cremaphor vehicle (10% cremaphor, 10% ethanol, 80% purified water).
Viruses
MA15 virus
The MA15 strain of SARS-CoV mouse-adapted virus was kindly
provided by Dr. Kanta Subbarao, National Institute of Health, NIAID,
designated “MA-15 3A-1 P1 in Vero cells 4/25/2005.” For cytokine
and lung pathology, MA15 virus was infected into BALB/c mice, and
then the mouse lung homogenates containing the virus were filtered
and subcultured again in Vero (ATCC CCL-81) cell culture for 2 days.
Cell culture homogenates were sonicated then frozen at −80 °C. For
all other in vivo work, the MA15 virus was subcultured in Vero-E6
cells in MEM with 10% FBS, 1 mM sodium pyruvate, and 0.1 mM non-
essential amino acids. After a 2-day incubation, cell culture homo-
genates were sonicated, centrifuged to clarify the solution, then
aliquoted and held frozen at−80 °C. Subcultured stocks were verified
by PCR using primers flanking characteristic mutations.
Urbani virus
Severe acute respiratory syndrome coronavirus (SARS-CoV), strain
Urbani (200300592), was obtained from the Centers for Disease
Control and Prevention (CDC, Atlanta, GA) and routinely passaged in
Vero-76 cells.
Mouse-adapted SARS-CoV v2163
Three BALB/c mice were anesthetized with ketamine/xylazine
mixture (approximately 100 mg/kg+5 mg/kg, respectively) and
infected with 50 or 100 μL of SARS-CoV Urbani virus solution by nasal
inhalation. Three or 5 days after infection, mice were euthanized, and
the lungs were removed and homogenized in 5mL of MEM+10% FBS.
The homogenate was tested for virus titer by CPE endpoint dilution
assay, then re-infected into a subsequent group of mice. These
infection steps continued for 25 passages, 5 passages with the
homogenate diluted 1:5, then 20 additional passages without dilution
of the lung homogenate between groups. This was determined to be
valid because control mice demonstrated no notable effect from
inhalation of uninfected lung tissue. One interim passage, P-12, was
plaque purified. Passages ceased when increased virus titer in the
lungs and signs of illness were observed in the infected animals. Lung
homogenate from passage 25 mice was filtered and subcultured in
Vero-76 cells, then diluted and plated to isolate single plaques. Plaque
purification in Vero-76 cells was repeated three times. Four isolated
plaques were subcultured in Vero-76 cells then compared by infecting
into BALB/c mice. The most virulent isolate was selected. Aliquots of
the virus stock were incubated in MEM medium for 7 days and
demonstrated no growth of extraneous bacteria or fungi. RNA was
isolated from the virus stock using the RNeasy kit (Qiagen, Alameda,
CA) and tested by qRT-PCR with two primer pairs to verify the
presence of SARS-CoV sequences (accession #AY278741). The
presence of SARS-CoV antigen in the virus stock was also demon-
strated using the SARS-CoV Ag Detection kit (Wantai, Inc., China). The
new virus stock was designated “SARS-CoV USU strain v2163” and
was used for subsequent studies. It is hereafter referred to as v2163.
Genome sequence
Sequence analysis was then performed at the University of North
Carolina. RNA was purified from the cell lysate of Vero-76 cells
infectedwith SARS-CoV v2163 using the RNeasy kit (Qiagen, Alameda,
CA) followed by first-strand cDNA synthesis by reverse transcription
using Superscript II (Invitrogen, Carlsbad, CA) as per the manufac-
turers' protocol. Reverse transcription was performed with an initial
incubation of 65 °C for 5 min then cooled on ice followed by a 50-min
incubation at 42 °C and a 5-min denaturation at 70 °C. Twomicroliters
of each cDNA reaction were amplified by PCR using Accuprime High
Fidelity Taq Polymerase (Invitrogen, Carlsbad, CA). Fifteen pairs of
primers were used to generate the overlapping PCR products spaced
every 2.5 kb generating DNA fragments with 500 bp overlap at each
end. Amplification products were visualized on agarose gels and
purified by use of the QIAquick Gel Extraction Kit (Qiagen, Alameda,
CA). PCR products were sequenced in both forward and reverse
directions with primers spaced every 500 bp along the genome.
Automated sequencing was performed utilizing the BigDye Termina-
tor version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA) as per manufacturer's instructions on an ABI Prism 3730 DNA
Analyzer (Applied Biosystems). Sequences were assembled and
analyzed with Vector NTI and Auto Assembler DNA Sequence
Assembly Software (ABI Prism; Applied Biosystems). When a
mutation was identified in comparison with the SARS-CoV published
sequence (Urbani accession #AY278741), independent RT-PCR reac-
tions were run and subsequent RT-PCR products were sequenced
through the region containing the putative mutation to confirm the
mutation.Mouse virulence studies
Mice 5–6 weeks old (14–16 g) were separated into groups of 10
mice for sacrifice on days 3 and 6 post-infection, and 9 or 10 mice for
weight and survival data. Mice were anesthetized by 0.1 mL
intraperitoneal injection of ketamine (100 mg/kg)/xylazine (5 mg/
kg) and then infected intranasally with a 50 μL suspension of the virus.
Mice were inoculated with approximately 105.5, 104.5, and 103.5
CCID50 of v2163 or MA15. Plaque assays were performed in Vero-76
cells on the actual inocula after infection and showed that the MA15
virus titer was equal or higher than that of the corresponding v2163
titer for both replicate experiments. As a wild-type control and for
comparison, mice were inoculated with approximately 105 CCID50 of
the Urbani SARS-CoV strain. Groups of 5 and 10 mice were sham
infected with MEM as a negative control. The groups of 10 survival
mice were weighed individually to the nearest 0.1 g each day, and
observed daily for death. Animals were held until death naturally
occurred or up to 21 d.p.i. Three days and 6 d.p.i., five survivors in each
groupwere euthanized and the lungs were removed. Lungs were then
diluted 1:20 in MEM+10% FBS, homogenized, and held at−80 °C for
virus titer testing. Lung homogenates were later thawed and serially
diluted in MEM+2% FBS in triplicate in 96-well plates to obtain
CCID50 values by the endpoint dilution method described below for
virus yield reduction assays. The mean day of death (MDD) was
calculated using mice that died and excluding survivors. The study
was repeated with 5- to 6-week-old mice and 10- to 11-week-old
(17–21 g) mice (Table 2). Another study was performed as above,
with just the 104.5 inoculum in BALB/c mice of various ages to
determine the age-dependent susceptibility to lethal infection.
Cytokine and chemokine analysis
Groups of 15mice (14–18 g) were inoculated intranasally with the
three virus strains suspended in 50 μL of MEM solution, and controls
were mock infected with saline. Inocula (CCID50 per mouse) were
4.1±0.3 log CCID50 for Urbani, 4.2±0.4 for v2163, and 4.0±0.5 for
MA15. On day 3 post-virus exposure, five surviving mice were
euthanized and the lungs were harvested. Remaining mice were held
for measurements of weight loss and death. Lung sections were saved
for histopathology in formalin solution. The remaining lung section
was diluted 1:20 in MEM solution and homogenized, then held frozen
at −80 °C. Samples were then tested for cytokines IL-1α, IL-1β, IL-2,
IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, TNF-α, GM-CSF, and IFN-γ, and for
chemokines MIP-1α, MCP-1, and RANTES using the Q-Plex™ mouse
cytokine array screen (Quansys Bioscience, Logan, UT), a quantitative
ELISA-based test withmultiple distinct capture antibodies absorbed to
each well of a 96-well plate in a defined array. Cytokines were
quantified by relative luminescence of each spot in the array, and
values (pg/mL) were calculated using the concurrently-run Quansys
Bioscience™ standard curve and the QuansysAnalysys™ software
(version 3.4). In one replicate some MCP-1 and RANTES values
exceeded the standard curve range and were estimated by extrapo-
lation (Fig. 3). Two of 10 v2163-inoculated mice had abnormally low
cytokines and were excluded as outliers because they had little or no
virus detected in the lungs. The cytokine results of all mice from two
experiments were combined for averages, standard deviation, and
Kruskal–Wallis analysis of variance followed by Dunn's multiple
comparison test compared to Urbani-infected mice.
Histopathology
Groups of animals were infected as described for the cytokine
assay above. After 3 days, lungs from sham controls and mice exposed
to 104 CCID50 Urbani, 104 v2163, and 105 MA15 were formalin-fixed.
Three lungs from each group were sectioned and stained with H&E
stain and evaluated by a board certified veterinary pathologist for
histopathological changes.
In vivo efficacy of drugs against v2163 infection
Groups of mice (16–19 g) were inoculated with 50 μL containing
104.0–4.4 CCID50 of v2163 virus by the i.n. route. Groups of mice were
administered 100 μL of the following drugs by the intraperitoneal
(i.p.) route: ribavirin at 37.5 mg/kg twice a day 8 h apart for 4 days
beginning 4 h prior to exposure to virus; Ampligen™ at 5 mg/kg for
four treatments 12–16 h apart beginning 16 h before virus exposure;
and physiological saline solution (PSS) as a placebo using the dosing
regimen described for ribavirin. In separate studies, 16- to 18-g mice
were treated with UDA at 5 mg/kg/day using the treatment regimen
described above for ribavirin, and 18- to 20-g mice were treated with
30 mg/kg/day of EP128533 protease suspended in 10% cremaphor
administered b.i.d. as above for 5 days beginning at time of infection.
Mice for toxicity controls were treated with PSS or cremaphor diluent
using the treatment regimens described above but without virus
exposure. Mice were observed daily, and group weights were taken
periodically throughout the test period. The average weight loss was
calculated on 3 d.p.i., and significance between treatments was
evaluated by one-way analysis of variance followed by Newman–
Keuls multiple comparison test. Compound toxicity in uninfected
mice was evaluated in terms of weight change and adverse events,
and no drug toxicity was observed in this study.
On days 3 and 6 post-infection, three to five surviving mice from
each treatment group were sacrificed. The remaining mice were held
and observed for death up to day 14 post-virus exposure (10 days for
UDA). Animals that lost greater than 30% of their initial bodyweight in
this experiment were humanely euthanized and the day of euthanasia
was designated as the day of death. Lungs from sacrificed mice were
observed for gross pathology and discoloration and assigned a score
ranging from 0 (normal appearing lung) to 4 (maximal plum
coloration in 100% of lung). Mouse lung samples from each test
group were pooled and homogenized in MEM solution and assayed in
duplicate for infectious virus using the method described below for
virus yield assays using triplicate wells of Vero-76 cells.
The procedures above were repeated in 15- to 18-g mice for IL-6,
histopathology, and virus titers in lungs (Table 4), andmultiple tissues
on 3 and 6 d.p.i. Lung sections were placed in formalin and examined
for histopathology as described above. Remaining lung portions were
homogenized individually in 2 mL of MEM+10% FBS and held frozen
at−80 °C. Sampleswere thawed,mixed, and then tested for IL-6 levels
using the eBioScience (SanDiego, CA) IL-6 ELISA kit permanufacturer's
instructions. Samples size was three per treatment group for
histopathology and four or five for IL-6 and virus titer depending on
number of survivors remaining. Values in pg/g of lungwere converted
to pg/mL corresponding with the 1:20 dilution used in the initial
untreated mice (Fig. 3). A low outlier in saline day 3 (655 pg/mL) was
included in results but excluded from statistical analysis. IL-6 levels in
treated groups were compared to untreated controls by ANOVA with
Newman–Keuls pairwise comparisons. Individual tissues were har-
vestedwith separate sterile instruments to ensure that each tissuewas
isolated from the lung during necropsy. Tissues were homogenized
and titers were performed as described for lungs above.
In vitro efficacy testing with strain v2163
The antiviral activity of test compounds was evaluated using the
v2163mouse-adapted virus strain as an in vitromodel comparedwith
strain Urbani run concurrently. Antiviral activity was measured by
inhibition of virus-induced cytopathic effect (CPE) (Sidwell and
Huffman, 1971), neutral red (NR) dye uptake (McManus, 1976), and
also by virus yield reduction assays. Vero-76 (ATCC CRL 1587) cells
grown inMEMwith 10% fetal bovine serum(FBS)were seeded into 96-well plates at a concentration of 2 × 104 cells per well and grown
overnight at 37 °C with 5% CO2. Test compounds were dissolved in
DMSO or water, then serially diluted in MEM by half-log dilutions in
triplicatewells. Testwellswere infectedwith amultiplicity of infection
(MOI) of less than 0.007 CCID50 per cell, sufficient to cause near
complete cytopathic effect (CPE) in 3 days, which was 1.6–2.1 log
CCID50 per well for Urbani, and 1.0–2.4 log CCID50 per well for v2163.
The test medium was MEM with 2% FBS and 50 μg/mL gentamicin.
Toxicity of compounds was assayed in duplicate wells without virus.
Plates were incubated as above for 3 days, then each well was read
microscopically for CPE. Cellswere incubatedwith0.011%NRdye for 2 h
at37 °C. Freedyewas removed from thewells, then theuptakendyewas
eluted with 50% ethanol in Sorensen citrate buffer for N30 min.
Absorbance was then measured as described by Finter (1969), with an
Opsys MRmicroplate reader (Dynex, Chantilly, VA) at 540 and 405 nm.
Absorbance values and visual CPEwere expressed as percentages of cell
controls and untreated virus controls, adjusted for toxicity. The 50%
effective concentration (EC50) and 50% inhibitory concentration
(cytotoxic, IC50) values were calculated by regression analysis.
Virus yield reduction assays were performed using the cell culture
50% infectious dose (CCID50) assay essentially as described previously
(Smee et al., 1992). Briefly, supernatants from each well were serially
diluted in triplicate wells of 96-well plates containing Vero-76 cells.
Plates were incubated for 6 days and then checked for virus-induced
CPE. Quantitation of virus yield titers was by the end point method of
Reed and Muench (1938). The EC90 value was calculated using linear
regression to estimate the concentration necessary to inhibit virus
yield by 90% or a one log10 decrease in virus titer. Results of at least
three assays were averaged and activity with the two virus strainswas
compared by Student's t test.
Statistical analyses
Statistical analyses were performed using PRISM™ 5.01 for
Windows, PRISM™ 4.0c for MAC (GraphPad Software, Inc., La Jolla,
CA), and Microsoft Excel 11.5. Comparisons not otherwise detailed
were performed by the Student's two-tailed t test assuming normal
distribution and equal variance, andmore sophisticated analyseswere
performed if differences were observed. The Kolmogorov–Smirnov
test (KS test) for normal distribution and Bartlett's test for equal
variance were performed as applicable. MDD, cytokine values, and
gross lung score data were analyzed by Mann–Whitney pairwise
comparisons or the Kruskal–Wallis test followed by Dunn's multiple
comparison test as applicable. Surviving animals were not included in
MDD calculations. Raw survival numbers were compared by the
Fisher exact test. Survivor curve analysis (as in Fig. 1) was done using
the Kaplan–Meier method and a log rank test. When that analysis
revealed significant differences among the treatment groups, pairwise
comparisons of survivor curves were analyzed by the Gehan–
Breslow–Wilcoxon test, and the relative significance was adjusted to
a Bonferroni-corrected significance threshold for the number of
treatment comparisons made. Differences in percent weight loss
were tested by one-way ANOVA with Newman–Keuls multiple
comparison test, assuming equal variance and normal distribution.
For lung titer data, we performed a KS test for normality, on log-
transformed values, then used non-parametric Kruskal–Wallis test
with Dunn's multiple comparison test for groups that were not
normally distributed, and a one-way ANOVA with Newman–Keuls
multiple comparison test for groups that were normally distributed.
LD50 was calculated using Probit analysis (StatPlus: MAC 2009).
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